What's Happening Now is a quick, thoughtful, real-time briefing regarding material events in the stem cell industry...definitely not the usual stream of insignificant press releases. The most current Happenings are boxed on the left-hand side of most pages on this site. Feel free to use this page to explore the archive of all past Happening items, and subscribe to the RSS feed to stay on top of the events that move the market and the industry.
Cytomedix Cuts Stroke Trial Enrollment by 52%, Closes Recruitment
Jan 6, 2014
Claiming a blinded interim analysis indicates its RECOVER-Stroke trial
is adequately powered with just 48 existing patients (out of 100 originally planned), Cytomedix
the early closure of recruitment. The company expects to announce top-line results in May. Last September it announced its intention to divest its stem cell therapeutic programs, which it acquired from Aldagen in 2012. Cytomedix "will continue to support the clinical study manufacturing requirements of the ongoing National Heart, Lung, and Blood Institute (NHLBI) sponsored Phase 2 PACE study in peripheral arterial disease," the cost of which is borne by NHLBI.
Cytomedix Restructures, Plans to Exit the Stem Cell Therapeutics Business
Sep 18, 2013
Perennial penny-stock Cytomedix
yesterday a reorganization and its intention to shutter its stem cell therapeutic development program, acquired in 2012 from Aldagen, by the end of the year.
Cytomedix Extends Overdue Stroke Trial, Adds Sites
Jul 30, 2013
< Previous Page
In its first update to the record for its clinical trial of stem cells for ischemic stroke in more than six months, Cytomedix
tacked more than a year onto the two and a half year-old trial's expected completion date and added two new sites. Our analysis of this trial's history is here
| Next Page >